Back to today’s briefing

Story perspectives

Bristol-Myers Squibb Faces Mixed Q3 Results Amid Rising Costs

10/27/2025

46 6

Summary

Story summary

Bristol-Myers Squibb is expected to report mixed third-quarter results, with Opdivo and Reblozyl driving sales at $2.43 billion and $583 million, respectively, per Zacks Consensus Estimates.
Bristol-Myers Squibb has underperformed the S&P 500 and its industry by 18.7% year-to-date, and trades at a forward P/E of 7.19.
Operating expenses are expected to rise in the second half of 2025 due to new investments.

1 of 1

Story summary

Bristol-Myers Squibb is expected to report mixed third-quarter results, with Opdivo and Reblozyl driving sales at $2.43 billion and $583 million, respectively, per Zacks Consensus Estimates.
Bristol-Myers Squibb has underperformed the S&P 500 and its industry by 18.7% year-to-date, and trades at a forward P/E of 7.19.
Operating expenses are expected to rise in the second half of 2025 due to new investments.